Compare · ADMS vs FPRX
ADMS vs FPRX
Side-by-side comparison of Adamas Pharmaceuticals, Inc. (ADMS) and Five Prime Therapeutics, Inc. (FPRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADMS and FPRX operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- ADMS carries a market cap of $373.6M.
- ADMS has more recent analyst coverage (5 ratings vs 0 for FPRX).
- Company
- Adamas Pharmaceuticals, Inc.
- Five Prime Therapeutics, Inc.
- Price
- $8.21+0.61%
- -
- Market cap
- $373.6M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2013
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Latest ADMS
- SEC Form SC 13G/A filed by Adamas Pharmaceuticals, Inc. (Amendment)
- SEC Form 15-12B filed by Adamas Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Adamas Pharmaceuticals, Inc.
- SEC Form 4: Bigham Michael closing all direct ownership in the company
- SEC Form 4: Mahoney David L closing all direct ownership in the company
- SEC Form 4: Prentiss Christopher B was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Mcfarlane Neil F. was granted 75,000 shares, closing all direct ownership in the company
- SEC Form 4: Ericson William W. closing all direct ownership in the company
- SEC Form 4: Shreedhar Vijay was granted 18,750 shares, closing all direct ownership in the company
- SEC Form 4: Papapetropoulos Spyridon closing all direct ownership in the company
Latest FPRX
- Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer
- SEC Form SC 13G/A filed by Five Prime Therapeutics, Inc. (Amendment)
- SEC Form 15-12B filed by Five Prime Therapeutics, Inc.
- SEC Form EFFECT filed by Five Prime Therapeutics, Inc.
- SEC Form 4: Sarena Francis Willard received a gift of 2,385 units of Common Stock, was granted 66,000 units of Common Stock, disposed of $6,530,414 worth of Common Stock back to the company (171,853 units at $38.00) and gifted 20,459 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy withholding obligation
- SEC Form 4: Smith David V was granted 66,000 units of Common Stock and disposed of $5,279,986 worth of Common Stock back to the company (138,947 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability
- SEC Form 4: Collins Helen Louise disposed of $5,150,786 worth of Common Stock back to the company (135,547 units at $38.00) , gifted 8,085 units of Common Stock and was granted 66,000 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy tax liability
- SEC Form 4: White David disposed of $1,270,074 worth of Common Stock back to the company (33,423 units at $38.00) , decreasing direct ownership by 100% to 0 units (tax withholding)
- SEC Form 4: RINGO WILLIAM R gifted 10,000 units of Common Stock, decreasing direct ownership by 100% to 0 units
- SEC Form 4: BERGER FRANKLIN M disposed of $190,000 worth of Common Stock back to the company (5,000 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability